Parkinson's Australia promotes the best possible quality of life for people with Parkinson’s.  This section provides evidence-based research to the Parkinson’s community on symptom management, and better care options for living well.  

01 Jan 2020

A Phase 3 study to evaluate efficacy, safety, and tolerability of ampreloxetine (TD-9855) in subjects with primary autonomic failures (MSA, PD, or PAF) and snOH with up to 4 weeks of treatment.

18 Aug 2020

At present, stem cell therapy is one of the most promising potential treatments of Parkinson’s as it enables renewal of dopaminergic neurons in the substantia nigra possible.

Stem cell therapy is based on cultivating stem cells and differentiating them to grow into dopamine secreting neurons which can be transplanted into the brain. Cultivating stem cells and maturing them requires additional application of growth factors which can induce turour growth after transplantation. Additionally, this method could have difficulties in growing fully matured cells resembling the brain neurons and have short life span.

The invention of nanostructures by a research team led by Professor Ken Yung Kin-lam, Professor of the Department of Biology and Dr Jeffrey Huang Zhifeng, Associate Professor of the Department of Physics at HKBU can stimulate growth of stem cells into miniature substantia nigra like stem cells (mini-SLSs).

The nanostructure or nanamatrix consist of a silica plate coated with trillions of nanozigzag structures which can initiate the growth of neural stem cells into mini-SLSs without the use of chemical growth factors.

The research team has further studied the nanomatrix in rat models of Parkinson’s where at 8 weeks rats showed improvements in motor symptoms.

14 Jun 2020

Stem cell research: Doctors at McLean Hospital and Massachusetts General Hospital have recently demonstrated the feasibility of using a patient’s own reprogrammed cells differentiating them to resemble the lost dopaminergic neurons.

21 May 2020

The US Food & Drug Administration have approved Apomorphine Hydrochloride for use in the US as an on-demand sublingual treatment for off episodes in people with Parkinson's.

17 May 2020

A great study from overseas. If needed, please use the English translation

Please reload

The content of this web site is intended to convey general educational information and should not be relied upon as a substitute for professional healthcare advice. 

© 2020 by Parkinson's Australia, PO Box 108, Deakin West, ACT 2600

ABN 46 011 714 078   

Parkinson's Australia Privacy Policy

Search this site